(Bethesda, Md.) -- The Cystic Fibrosis Foundation today lauded the U.S. House of Representatives for passing legislation to reauthorize the Small Business Innovation Research (SBIR) program.
In response to testimony from Robert J. Beall, Ph.D., president and CEO of the Foundation, the legislation includes a provision requiring that special attention be given to research for rare diseases, such as cystic fibrosis, when SBIR grants are awarded.
The SBIR program provides grants to small biotechnology and pharmaceutical companies for research and development programs focused on innovative treatments for rare diseases.
“We congratulate members of the House for recognizing the importance of funding for rare disease research and how critical these dollars are for cystic fibrosis and other devastating illnesses,” said Beall. “The SBIR grants have been an important catalyst for several of our biotech collaborators working to find a cure. This special focus for the program is a win-win for everyone.”
The Cystic Fibrosis Foundation was one of 20 organizations that supported the inclusion of rare disease research as an area of research that is “deserving of special attention in the SBIR program's
The legislation now moves to the U.S. Senate for consideration.
About the Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis. The CF Foundation funds more cystic fibrosis research than any other organization, and nearly every CF drug available today was made possible because of CF Foundation support. Based in Bethesda, Md., the CF Foundation also supports and accredits a national care center network that has been recognized by the National Institutes of Health as a model of care for a
Laurie Fink, national director of media relations: 301-841-2602; email@example.com